Published in J Clin Microbiol on December 26, 2012
Characterization of the RelBbu regulon in borrelia burgdorferi reveals modulation of glycerol metabolism by (p)ppGpp. PLoS One (2015) 1.45
Borrelia burgdorferi, the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells. Antimicrob Agents Chemother (2015) 1.08
Stage-specific global alterations in the transcriptomes of Lyme disease spirochetes during tick feeding and following mammalian host adaptation. Mol Microbiol (2014) 1.00
A Highly Expressed Human Protein, Apolipoprotein B-100, Serves as an Autoantigen in a Subgroup of Patients With Lyme Disease. J Infect Dis (2015) 0.86
Persister Development by Borrelia burgdorferi Populations In Vitro. Antimicrob Agents Chemother (2015) 0.85
Sensitive multiplex PCR assay to differentiate Lyme spirochetes and emerging pathogens Anaplasma phagocytophilum and Babesia microti. BMC Microbiol (2013) 0.84
Relevance of chronic lyme disease to family medicine as a complex multidimensional chronic disease construct: a systematic review. Int J Family Med (2014) 0.78
Quantification of Borrelia burgdorferi Membrane Proteins in Human Serum: A New Concept for Detection of Bacterial Infection. Anal Chem (2015) 0.77
Measurements of mRNA degradation in Borrelia burgdorferi. J Bacteriol (2013) 0.76
Borrelia burgdorferi induces a type I interferon response during early stages of disseminated infection in mice. BMC Microbiol (2016) 0.76
Cutaneous Lyme borreliosis: Guideline of the German Dermatology Society. Ger Med Sci (2017) 0.75
The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis (2006) 13.01
Persister cells, dormancy and infectious disease. Nat Rev Microbiol (2006) 8.35
Persister cells. Annu Rev Microbiol (2010) 7.24
Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med (2001) 6.67
A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology (2007) 5.86
Polynucleotide phosphorylase and ribonuclease II are required for cell viability and mRNA turnover in Escherichia coli K-12. Proc Natl Acad Sci U S A (1986) 4.97
Clonal polymorphism of Borrelia burgdorferi strain B31 MI: implications for mutagenesis in an infectious strain background. Infect Immun (2002) 3.65
Subjective symptoms after treatment of early Lyme disease. Am J Med (2010) 3.22
Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology (2003) 3.03
Diagnosis of early Lyme disease by polymerase chain reaction amplification and culture of skin biopsies from erythema migrans lesions. J Clin Microbiol (1992) 2.69
Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy. J Clin Invest (2012) 2.44
Detection of mRNA by reverse transcription-PCR as an indicator of viability in Escherichia coli cells. Appl Environ Microbiol (1998) 2.38
Fate of Borrelia burgdorferi DNA in tissues of infected mice after antibiotic treatment. J Infect Dis (1994) 2.09
Detection of attenuated, noninfectious spirochetes in Borrelia burgdorferi-infected mice after antibiotic treatment. J Infect Dis (2002) 2.05
Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob Agents Chemother (2008) 2.02
Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. PLoS One (2012) 2.01
Impact of genotypic variation of Borrelia burgdorferi sensu stricto on kinetics of dissemination and severity of disease in C3H/HeJ mice. Infect Immun (2001) 1.93
Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J Clin Microbiol (1997) 1.83
Molecular methods for the assessment of bacterial viability. J Microbiol Methods (2003) 1.68
Long-term follow-up of patients with culture-confirmed Lyme disease. Am J Med (2003) 1.62
Ineffectiveness of tigecycline against persistent Borrelia burgdorferi. Antimicrob Agents Chemother (2009) 1.60
Antibiotic treatment of animals infected with Borrelia burgdorferi. Clin Microbiol Rev (2009) 1.51
Burden and viability of Borrelia burgdorferi in skin and joints of patients with erythema migrans or lyme arthritis. Arthritis Rheum (2011) 1.44
PCR-Based quantification of Borrelia burgdorferi organisms in canine tissues over a 500-Day postinfection period. J Clin Microbiol (2000) 1.35
Improving the yield of blood cultures from patients with early Lyme disease. J Clin Microbiol (2011) 1.22
The role of RNA stability during bacterial stress responses and starvation. Environ Microbiol (2000) 1.22
"Persisters": survival at the cellular level. PLoS Pathog (2011) 1.19
Destruction of spirochete Borrelia burgdorferi round-body propagules (RBs) by the antibiotic tigecycline. Proc Natl Acad Sci U S A (2009) 1.15
Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice. Antimicrob Agents Chemother (1994) 1.11
In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics. Infection (1996) 1.03
The amber theory of Lyme arthritis: initial description and clinical implications. Clin Rheumatol (2012) 0.97
Nucleic acids as viability markers for bacteria detection using molecular tools. Future Microbiol (2009) 0.97
A comparison of nucleic acid amplification techniques for the assessment of bacterial viability. Lett Appl Microbiol (2001) 0.96
In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites. Antimicrob Agents Chemother (1996) 0.95
Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice. Antimicrob Agents Chemother (2002) 0.94
Critical analysis of treatment trials of rhesus macaques infected with Borrelia burgdorferi reveals important flaws in experimental design. Vector Borne Zoonotic Dis (2012) 0.89
Effect of post-treatment holding conditions on detection of tufA mRNA in ethanol-treated Escherichia coli: implications for RT-PCR-based indirect viability tests. Lett Appl Microbiol (1999) 0.87
Comparison of in vitro activities of tigecycline, doxycycline, and tetracycline against the spirochete Borrelia burgdorferi. Ticks Tick Borne Dis (2010) 0.85
Development of a real-time RT-PCR method for enumeration of viable Bifidobacterium longum cells in different morphologies. Food Microbiol (2009) 0.84
Relationship of messenger RNA reverse transcriptase-polymerase chain reaction signal to Campylobacter spp. viability. Avian Dis (2004) 0.82
A critical appraisal of "chronic Lyme disease". N Engl J Med (2007) 7.84
Lyme borreliosis. Lancet (2011) 4.81
Diagnosis of lyme borreliosis. Clin Microbiol Rev (2005) 4.48
Differentiation of reinfection from relapse in recurrent Lyme disease. N Engl J Med (2012) 3.79
Subjective symptoms after treatment of early Lyme disease. Am J Med (2010) 3.22
Profiling of temperature-induced changes in Borrelia burgdorferi gene expression by using whole genome arrays. Infect Immun (2003) 3.19
Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. J Infect Dis (2003) 3.18
Antiscience and ethical concerns associated with advocacy of Lyme disease. Lancet Infect Dis (2011) 2.88
Common misconceptions about Lyme disease. Am J Med (2013) 2.84
Treatment trials for post-Lyme disease symptoms revisited. Am J Med (2013) 2.75
MLST of housekeeping genes captures geographic population structure and suggests a European origin of Borrelia burgdorferi. Proc Natl Acad Sci U S A (2008) 2.67
Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms. Brain Behav Immun (2010) 2.50
Analysis of the RpoS regulon in Borrelia burgdorferi in response to mammalian host signals provides insight into RpoS function during the enzootic cycle. Mol Microbiol (2007) 2.32
Borrelia burgdorferi genotype predicts the capacity for hematogenous dissemination during early Lyme disease. J Infect Dis (2008) 2.26
Southern Tick-Associated Rash Illness (STARI) in the North: STARI following a tick bite in Long Island, New York. Clin Infect Dis (2011) 2.19
Human Borrelia miyamotoi infection in the United States. N Engl J Med (2013) 2.11
Disease severity in a murine model of lyme borreliosis is associated with the genotype of the infecting Borrelia burgdorferi sensu stricto strain. J Infect Dis (2002) 1.97
The propensity of different Borrelia burgdorferi sensu stricto genotypes to cause disseminated infections in humans. Am J Trop Med Hyg (2008) 1.82
Reinfection in patients with Lyme disease. Clin Infect Dis (2007) 1.81
Efficacy of antibiotic prophylaxis for the prevention of Lyme disease: an updated systematic review and meta-analysis. J Antimicrob Chemother (2010) 1.75
Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis (2008) 1.71
An outbreak of mycobacterial furunculosis associated with footbaths at a nail salon. N Engl J Med (2002) 1.69
Serologic markers of Lyme disease in children with autism. JAMA (2013) 1.67
Long-term follow-up of patients with culture-confirmed Lyme disease. Am J Med (2003) 1.62
Empiric antibiotic treatment of erythema migrans-like skin lesions as a function of geography: a clinical and cost effectiveness modeling study. Vector Borne Zoonotic Dis (2013) 1.59
Antibiotic treatment of animals infected with Borrelia burgdorferi. Clin Microbiol Rev (2009) 1.51
Chlorhexidine bathing to reduce central venous catheter-associated bloodstream infection: impact and sustainability. Am J Med (2012) 1.50
Electrical twitch-obtaining intramuscular stimulation in lower back pain: a pilot study. Am J Phys Med Rehabil (2004) 1.49
Rrp1, a cyclic-di-GMP-producing response regulator, is an important regulator of Borrelia burgdorferi core cellular functions. Mol Microbiol (2009) 1.45
Single-dose prophylaxis against Lyme disease. Lancet Infect Dis (2007) 1.45
Analysis of sequences and loci of p44 homologs expressed by Anaplasma phagocytophila in acutely infected patients. J Clin Microbiol (2002) 1.45
Why has Borrelia burgdorferi not been transmitted by blood transfusion? Transfusion (2013) 1.42
Poly-ticks: Blue State versus Red State for Lyme disease. Lancet (2005) 1.42
Quantitative detection of Borrelia burgdorferi in 2-millimeter skin samples of erythema migrans lesions: correlation of results with clinical and laboratory findings. J Clin Microbiol (2002) 1.40
Interaction and transmission of two Borrelia burgdorferi sensu stricto strains in a tick-rodent maintenance system. Appl Environ Microbiol (2004) 1.38
Fitness variation of Borrelia burgdorferi sensu stricto strains in mice. Appl Environ Microbiol (2007) 1.36
Comparative genome hybridization reveals substantial variation among clinical isolates of Borrelia burgdorferi sensu stricto with different pathogenic properties. J Bacteriol (2006) 1.34
Linear and circular plasmid content in Borrelia burgdorferi clinical isolates. Infect Immun (2003) 1.33
Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol (2012) 1.30
Borrelia burgdorferi basic membrane proteins A and B participate in the genesis of Lyme arthritis. J Exp Med (2007) 1.29
Babesiosis in Lower Hudson Valley, New York, USA. Emerg Infect Dis (2011) 1.24
Natural history of colonization with vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and resistant gram-negative bacilli among long-term-care facility residents. Infect Control Hosp Epidemiol (2003) 1.24
Improving the yield of blood cultures from patients with early Lyme disease. J Clin Microbiol (2011) 1.22
Bartonella spp. transmission by ticks not established. Emerg Infect Dis (2010) 1.19
Epitope mapping of antibodies to VlsE protein of Borrelia burgdorferi in post-Lyme disease syndrome. Clin Immunol (2011) 1.18
Recognition of Borrelia burgdorferi, the Lyme disease spirochete, by TLR7 and TLR9 induces a type I IFN response by human immune cells. J Immunol (2009) 1.18
Borrelia burgdorferi gene expression profiling with membrane-based arrays. Methods Enzymol (2002) 1.16
Borrelia burgdorferi sensu stricto is clonal in patients with early Lyme borreliosis. Appl Environ Microbiol (2008) 1.16
2-tiered antibody testing for early and late Lyme disease using only an immunoglobulin G blot with the addition of a VlsE band as the second-tier test. Clin Infect Dis (2010) 1.15
Borrelia burgdorferi bba74 is expressed exclusively during tick feeding and is regulated by both arthropod- and mammalian host-specific signals. J Bacteriol (2009) 1.14
Impaired host defense to infection and Toll-like receptor 2-independent killing of Borrelia burgdorferi clinical isolates in TLR2-deficient C3H/HeJ mice. FEMS Microbiol Lett (2004) 1.13
Borrelia miyamotoi sensu lato seroreactivity and seroprevalence in the northeastern United States. Emerg Infect Dis (2014) 1.13
Comparative transcriptional profiling of Borrelia burgdorferi clinical isolates differing in capacities for hematogenous dissemination. Infect Immun (2005) 1.11
Seroprevalence of antibodies that react with Anaplasma phagocytophila, the agent of human granulocytic ehrlichiosis, in different populations in Westchester County, New York. J Clin Microbiol (2002) 1.11
A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wien Klin Wochenschr (2005) 1.10
Comparison of five diagnostic modalities for direct detection of Borrelia burgdorferi in patients with early Lyme disease. Diagn Microbiol Infect Dis (2012) 1.10
Microbiologic evaluation of patients from Missouri with erythema migrans. Clin Infect Dis (2005) 1.10
Anti-Borrelia burgdorferi antibody profile in post-Lyme disease syndrome. Clin Vaccine Immunol (2011) 1.09
Variations in Barbour-Stoenner-Kelly culture medium modulate infectivity and pathogenicity of Borrelia burgdorferi clinical isolates. Infect Immun (2004) 1.08
MonoMAC syndrome in a patient with a GATA2 mutation: case report and review of the literature. Clin Infect Dis (2013) 1.08
Multilocus sequence typing of Borrelia burgdorferi suggests existence of lineages with differential pathogenic properties in humans. PLoS One (2013) 1.07
Borrelia burgdorferi requires glycerol for maximum fitness during the tick phase of the enzootic cycle. PLoS Pathog (2011) 1.06
Effect of Borrelia burgdorferi genotype on the sensitivity of C6 and 2-tier testing in North American patients with culture-confirmed Lyme disease. Clin Infect Dis (2008) 1.03
Real-time PCR for simultaneous detection and quantification of Borrelia burgdorferi in field-collected Ixodes scapularis ticks from the Northeastern United States. Appl Environ Microbiol (2003) 1.02
Recombinant assay for serodiagnosis of Lyme disease regardless of OspA vaccination status. J Clin Microbiol (2002) 1.02
Identification and molecular characterization of a cyclic-di-GMP effector protein, PlzA (BB0733): additional evidence for the existence of a functional cyclic-di-GMP regulatory network in the Lyme disease spirochete, Borrelia burgdorferi. FEMS Immunol Med Microbiol (2009) 1.01
Src family protein tyrosine kinase regulates the basolateral K channel in the distal convoluted tubule (DCT) by phosphorylation of KCNJ10 protein. J Biol Chem (2013) 1.01
Stage-specific global alterations in the transcriptomes of Lyme disease spirochetes during tick feeding and following mammalian host adaptation. Mol Microbiol (2014) 1.00
Biodiversity of Borrelia burgdorferi strains in tissues of Lyme disease patients. PLoS One (2011) 1.00
A decline in C6 antibody titer occurs in successfully treated patients with culture-confirmed early localized or early disseminated Lyme Borreliosis. Clin Diagn Lab Immunol (2005) 0.99
Erythromycin resistance in Borrelia burgdorferi. Antimicrob Agents Chemother (2002) 0.98
Lyme disease and human granulocytic anaplasmosis coinfection: impact of case definition on coinfection rates and illness severity. Clin Infect Dis (2012) 0.98
Borrelia burgdorferi RNA induces type I and III interferons via Toll-like receptor 7 and contributes to production of NF-κB-dependent cytokines. Infect Immun (2014) 0.97
The amber theory of Lyme arthritis: initial description and clinical implications. Clin Rheumatol (2012) 0.97
Borrelia burgdorferi BBA74, a periplasmic protein associated with the outer membrane, lacks porin-like properties. J Bacteriol (2006) 0.95
Blood cultures for patients with extracutaneous manifestations of Lyme disease in the United States. Clin Infect Dis (2009) 0.94
Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice. Antimicrob Agents Chemother (2002) 0.94
Borrelia burgdorferi vlsE antigenic variation is not mediated by RecA. Infect Immun (2008) 0.93
A systematic review of Borrelia burgdorferi morphologic variants does not support a role in chronic Lyme disease. Clin Infect Dis (2013) 0.93
Comparison of erythema migrans caused by Borrelia burgdorferi and Borrelia garinii. Vector Borne Zoonotic Dis (2011) 0.92
Oral doxycycline for neuroborreliosis. Lancet Neurol (2008) 0.92
BBK07 immunodominant peptides as serodiagnostic markers of Lyme disease. Clin Vaccine Immunol (2010) 0.91